

Wednesday 2 October 2019 – Day 1

BSHT PhD/Early Post-doc Session

Hall: Lomond

- **09.00 – 09.20:** Fibrin films and where to find them, **Fraser Macrae**, University of Leeds
- **09.20 – 09.40:** Factor XII driven coagulation, **Lewis Hardy**, University of Leeds
- **09.40 – 10.00:** Allosteric activation of ADAMTS13, **Tassos Petri**, Imperial College London

09.00 – 10.00

BSHT PhD/Early Post-doc Session

Hall: Alsh

- **09.00 – 09.15:** Dihomo- γ -linolenic acid enhances aspirin-mediated inhibition and alters the proteomic releasate profile in platelets, **Laura Menke**, Queen Mary University London
- **09.15 – 09.30:** The differential requirement of the Btk kinase domain downstream of ITAM and hemITAM signalling, **Sophie Nock**, University of Reading
- **09.30 – 09.45:** Multicolour flow cytometry reveals platelet subpopulations that are regulated by prostacyclin, **Matt Hindle**, Queen Mary University London
- **09.45 – 10.00:** Platelet ageing causes changes in key metabolic and structural proteins, **Harriet Allan**, Queen Mary University London

10.00 – 10.30

Coffee Break and Poster Viewing

BSHT Session

Hall: Lomond

- **10.30 – 11.05:** Novel prothrombin variant causing inherited thrombophilia, **Vincent Muczynski**, University College London
- **11.05 – 11.40:** VWF, platelets and neutrophils – novel roles of GPIIb α , allbb3 and SLC44A2, **Isabelle Salles-Crawley**, Imperial College London
- **11.40 – 12.15:** Thrombotic Thrombocytopenic Purpura (TTP) – from pathogenesis of disease to treatment, **Mari Thomas**, University College London

10.30 – 12.15

The Platelet Society Session

Hall: Alsh

- **10.30 – 11.05:** Repurposing anti-cancer drugs, could Pim kinase inhibitors be the new aspirin? **Amanda Unsworth**, Manchester Metropolitan University
- **11.05 – 11.40:** Platelet factor XIII-A regulates platelet function and promotes clot retraction and stability, **Jo Mitchell**, University of Reading
- **11.40 – 12.15:** Recombinant Von Willebrand Factor (Vonvendi) mediates acute reversal of platelet dysfunction induced by antiplatelet agents, **Alex Bye**, University of Reading

BSH Sessions

Hall: Boisdale

- **10.30 – 11.05:** Refractory thrombotic thrombocytopenic purpura: Why and how I treat, **Tina Duff**, Royal Liverpool University Hospital
- **11.05 – 11.40:** Refractory immune thrombocytopenic purpura: Why and how I treat, **Nichola Cooper**, Imperial College London
- **11.40 – 12.15:** Recurrent thrombosis in anti-phospholipid syndrome: Why and how I treat, **Hannah Cohen**, University College London



12.15 – 13.15

Lunch Break

Special Symposium

(not part of main CME/CPD programme)

13.15 – 14.45

**Venous Thrombosis :
Risk**

Oral Communication

Hall : Lomond

Details on page 6

**Bleeding Disorders
and Therapy**

Oral Communication

Hall : Alsh

Details on page 6

Basic Clotting

Oral Communication

Hall : Boisdale

Details on page 6-7

Platelets 1

Oral Communication

Hall : Carron

Details on page 7

14.45 – 15.00

Coffee Break and Poster Viewing

15.00 – 16.00

Plenary Session

Hall: Lomond

*A History of Scottish Medicine, **Gordon Lowe**, United Kingdom*

16.00 – 16.30

Coffee Break and Poster Viewing

16.30 – 17.30

Science Fast and Furious

Hall : Lomond

Details on page 7

17.30 – 18.00

Opening Ceremony

Hall : Lomond

18.00 – 19.00

Welcome Reception

Thursday 3 October 2019 – Day 2

08.30 – 08.55

Meet the Expert

- Meet the expert 1
- Meet the expert 2
- Meet the expert 3
- Meet the expert 4
- Meet the expert 5

How to...

- How to 1
- How to 2
- How to 3
- How to 4
- How to 5

08.55 – 09.20

Meet the Expert

- Meet the expert 6
- Meet the expert 7
- Meet the expert 8
- Meet the expert 9
- Meet the expert 10

How to...

- How to 6
- How to 7
- How to 8
- How to 9
- How to 10

09.20 – 09.30

Short Break

09.30 – 10.30

Focus Symposium

Thrombosis and
Cancer

Hall : Lomond

Details on page 8

Focus Symposium

Treatment of
Haemophilia

Hall : Alsh

Details on page 8

Focus Symposium

Translational Science

Hall: Boisdale

Details on page 8

Focus Symposium

Anticoagulant
Proteins

Hall : Carron

Details on page 8

10.30 – 11.00

Coffee Break and Poster Viewing

11.00 – 11.30

State of the Art

A dual role for platelets in fibrinolysis

Nicola Mutch, United Kingdom

Hall: Lomond

State of the Art

Vascular calcification

Leon Schurgers, The Netherlands

Hall: Alsh

11.30 – 12.00

State of the Art

Management in von Willebrand disease

Jeroen Eikenboom, The Netherlands

Hall: Lomond

State of the Art

Coagulation factors crosstalk with endothelium

Pablo Garcia de Frutos, Spain

Hall: Alsh



12.00 – 12.15

Short Break

12.15 – 13.15

Special Symposium

*(not part of main
CME/CPD
programme)*

Special Symposium

*(not part of main
CME/CPD
programme)*

Special Symposium

*(not part of main
CME/CPD
programme)*

Special Symposium

*(not part of main
CME/CPD
programme)*

13.15 – 13.30

Short Break

13.30 – 14.30

Plenary Session

Hall: Lomond

*New development in Von Willebrand research, **Cécile Denis**, France*

14.30 – 15.15

Contact Activation

Oral Communication

Hall : Lomond

Details on page 8

**Von Willebrand
Disease**

Oral Communication

Hall : Alsh

Details on page 9

Vessel Wall 1

Oral Communication

Hall : Boisdale

Details on page 9

Platelets

Oral Communication

Hall : Carron

Details on page 9

15.15 – 15.45

Coffee Break and Poster Viewing

15.45 – 17.00

Clotting

*Invited Integrated
Symposium*

Platelets

*Invited Integrated
Symposium*

Vessel Wall

*Invited Integrated
Symposium*

Bleeding

*Invited Integrated
Symposium*

17.00 – 18.30

Poster Reception

17.30 – 18.30

Poster Sessions

Please see "Poster Overview" on the ECTH website

18.30 – 19.30

Congress Dinner

Venue : To be confirmed

Friday 4 October 2019 – Day 3

Venous Thrombosis : Consequences

Oral Communication

Hall : Lomond

Details on page 10

Bleeding in the Clinic

Oral Communication

Hall : Alsh

Details on page 10

Clot Structure

Oral Communication

Hall : Boisdale

Details on page 10

Vessel Wall 2

Oral Communication

Hall : Carron

Details on page 10

09.00 – 10.00

10.00 – 10.30

Coffee Break and Poster Viewing

10.30 – 11.00

State of the Art

Overview on HUS: novel treatment

Marina Noris, Italy

Hall: Lomond

State of the Art

Phosphatases in platelet signalling

Yotis Senis, United Kingdom

Hall: Alsh

11.00 – 11.30

State of the Art

Nets

Kimberly Martinod, Belgium

Hall: Lomond

State of the Art

Bleeding

Samantha Gouw, The Netherlands

Hall: Alsh

11.30 – 12.30

Science Fast and Furious

Hall : Lomond

Details on page 11

12.30 – 13.30

Lunch Break and Poster Viewing

Sport Activity

13.30 – 14.30

Plenary Session

Hall : Lomond

*Current status of inhibitors of factor XI, **Jeffrey Weitz**, Canada*

14.30 – 14.45

Closing and ECTH2021

Wednesday

Venomous Thrombosis: Risk

- **13.15 – 13.30:** The effect of thrombophilic risk factors on VTE risk in orthopaedic surgical patients: results of a large population-based case-control study, **Carolina Touw**, The Netherlands
- **13.30 – 13.45:** Plasma levels of a complement factor H related protein are associated with VTE, **Maria Jesus Iglesias**, Norway
- **13.45 – 14.00:** Thrombosis risk after switching oral contraceptive type, **Deeksha Khialani**, The Netherlands
- **14.00 – 14.15:** Impact of dietary intake of marine n-3 polyunsaturated fatty acids on surgery as a trigger for venous thromboembolism: results from a case-crossover study, **Trond Isaksen**, Norway
- **14.15 – 14.30:** Splanchnic vein thrombosis and antithrombin deficiency, **María Eugenia De La Morena-Barrio**, Spain
- **14.30 – 14.45:** Combined effect between genetic risk factors and pregnancy/postpartum period on the risk of venous thrombosis, **Sara Arcudi**, Italy

Bleeding Disorders and Therapy

- **13.15 – 13.30:** Surgical experience from four phase III studies (HAVEN 1–4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors, **Elena Santagostino**, United Kingdom
- **13.30 – 13.45:** Functional investigation of a CD36 variant in patients with an inherited bleeding disorder, **Ibrahim Almazni**, United Kingdom
- **13.45 – 14.00:** Antithrombotic therapy with an anti-glycoprotein VI humanized Fab does not increase the risk of inflammation-associated bleeding in mice, **Soumaya Jadoui**, France
- **14.00 – 14.15:** Modulation of alternative splicing of the F5 gene using morpholino antisense oligonucleotides, **Alice Todaro**, The Netherlands
- **14.15 – 14.30:** Functional characterization of FV deficiency in Norway: Effects of F5 mutations on secretion, endoplasmic reticulum stress, apoptosis, and activated protein C sensitivity, **Nina Iversen**, Norway
- **14.30 – 14.45:** Evaluation of different therapeutic strategies to manage the rare coagulation defect due to enhanced protein C activity induced by the thrombomodulin c.1611C>Ap.Cys537Stop mutation, **Gael Morrow**, United Kingdom

Basic Clotting

- **13.15 – 13.30:** Repetitive genomic sequences and their role in antithrombin deficiency, **Belén De La Morena-Barrio**, Spain
- **13.30 – 13.45:** Fine mapping of anti-spacer autoantibodies from immune-mediated thrombotic thrombocytopenic purpura patients using ADAMTS13/ADAMTS1 spacer hybrids, **Leydi Carolina Velasquez Pereira**, Belgium
- **13.45 – 14.00:** Partial rescue of naturally occurring active site factor X variants through decreased inhibition by tissue factor pathway inhibitor and antithrombin, **Josefin Ahnström**, United Kingdom
- **14.00 – 14.15:** Thrombosis and genetics: is p.Arg541Trp the future Breizh prothrombin?, **Alexandre Fauché**, France
- **14.15 – 14.30:** Comparison of the procoagulant activity of extracellular vesicles obtained from cellular monolayers and spheroids, **Araci Rondon**, The Netherlands

- **14.30 – 14.45:** The critical role of tissue factor pathway inhibitor (TFPI) under flow and in vivo, **Parvathy Sasikumar**, United Kingdom

Platelets 1

- **13.15 – 13.30:** NOX1 inhibitors suppress collagen-stimulated platelet activation in vitro and endothelial damage-induced carotid occlusion in vivo with no effect on haemostasis, **Dina Vara**, United Kingdom
- **13.30 – 13.45:** Critical role of platelets during lung fibrosis, **Raphaël Martos**, France
- **13.45 – 14.00:** Platelet integrin alphaIIb beta3 and phosphatidylserine are vital in extracellular vesicle release from activated platelets, **Alexandra Heinzmann**, The Netherlands
- **14.00 – 14.15:** Deep Phenotyping of Platelet Sensitivity and Response Capacity, **Joanne Dunster**, United Kingdom
- **14.15 – 14.30:** Novel platelet-neutrophil interaction between activated alphaIIb beta3 and SLC44A2 mediates NETosis under flow, **Adela Constantinescu-Bercu**, United Kingdom
- **14.30 – 14.45:** Towards a quantitative ex vivo assessment of the innate immune system participation in thrombus formation, **Daria Morozova**, Russia

Science, Fast and Furious

- **16.30 – 16.45:** Hypertensive complications of pregnancy and risk of venous thromboembolism: a population based cohort study in 2 million pregnant women, **Luuk Scheres**, The Netherlands
- **16.45 – 17.00:** In vitro and in vivo modulation of von Willebrand factor gene mutations with dominant-negative effect, **Caterina Casari**, France
- **17.00 – 17.15:** The Use of In Vitro Clot Lysis Assay For Predicting Outcomes and Safety In Acute Ischemic Stroke Patients Undergoing Intravenous Thrombolysis, **Zsuzsa Bagoly**, Hungary
- **17.15- 17.30:** Identification of a low shear stress-specific anti-thrombotic pathway in the microvasculature orchestrated by the endothelial transcription factor ERG, **Claire Peghaire**, United Kingdom

Thursday

Thrombosis and Cancer

- **9.30 – 10.00:** VTE therapy in patients with Cancer, **Manuel Monreal**, Spain
- **10.00 – 10.15:** Platelets promote metastatic dissemination in mouse and human models in vivo and are associated with reduced survival in lung adenocarcinoma patients, **Stephanie Hyslop**, Australia
- **10.15 – 10.30:** The impact of second cancer on the risk of cancer associated venous thromboembolism; a Danish nationwide study, **Inger Lise Gade**, Denmark

Treatment of Haemophilia

- **9.30 – 10.00:** Treatment of Haemophilia, **Roger Schutgens**, The Netherlands
- **10.00 – 10.15:** A fully-human bispecific antibody for the treatment of hemophilia A, **John Blackwood**, United Kingdom
- **10.15 – 10.30:** Emicizumab demonstrates long term efficacy and tolerability in a broad population of persons with haemophilia A (PwHA) with or without FVIII inhibitors: pooled data from four HAVEN studies, **Guy Young**, United States

Translational Science

- **9.30 – 10.00:** Protein S – at the centre of haemostatic regulation, **Josefin Ahnstrom**, United Kingdom
- **10.00 – 10.15:** In Silico Peptide Design: from molecular mechanism to novel therapeutic treatments for inflammatory diseases, **Kanin Wichapong**, The Netherlands
- **10.15 – 10.30:** Targeting CXCL1-deposition on the vessel wall with a tick-derived protein, **Ingrid Dijkgraaf**, The Netherlands

Anticoagulant Proteins

- **9.30 – 10.00:** Microparticles, ready for the clinics?, **Françoise Dignat-George**, France
- **10.00 – 10.15:** Characterisation of citrullinated TFPI and truncated TFPI constructs by PAD4 in model and plasma systems, **Stella Thomassen**, The Netherlands
- **10.15 – 10.30:** Molecular, biological and clinical characterization of variants affecting the C-terminal end of antithrombin, **Bravo-Perez Carlos**, Spain

Contact Activation

- **14.30 – 14.45:** Factor XII proline rich domain is essential for contact activation, **Marco Heestermaans**, Germany
- **14.45 – 15.00:** High molecular weight kininogen but not factor XII deficiency protects against acetaminophen-induced hepatotoxicity in mice, **Rafal Pawlinski**, United States
- **15.00 – 15.15:** uPA-mediated plasminogen activation is enhanced by polyphosphate, **Claire Whyte**, United Kingdom

Von Willebrand Disease

- **14.30 – 14.45:** Endothelial cells derived from induced pluripotent stem cells have the potential to model von Willebrand Disease, **Matthew Sims**, United Kingdom
- **14.45 – 15.00:** Acquired Von Willebrand syndrome associated with monoclonal gammopathy, **Eugenia Biguzzi**, Italy
- **15.00 – 15.15:** Determination of prevalence and features of main VWF synonymous variants of the CRMW database, **Fanny Lassalle**, France

Vessel Wall 1

- **14.30 – 14.45:** TLR3 promotes venous thrombosis through neutrophil recruitment, **Maria Najem**, France
- **14.45 – 15.00:** CTL-2 is a VWF receptor involved in neutrophil activation, **Gaia Zirka**, France
- **15.00 – 15.15:** DNase-dependent but NETs-independent pathways of thrombus formation in vivo, **Estelle Carminita**, France

Platelets 2

- **14.30 – 14.45:** Allelic polymorphism of platelet glycoprotein genes GPIa and GPIIb as a possible predictive marker of response to therapy in patients with primary immune thrombocytopenia, **Irina Zotova**, Russia
- **14.45 – 15.00:** Platelet biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis, **Alessandro Ciavarella**, Italy
- **15.00 – 15.15:** Effect of antiplatelet agents on bacterial induced platelet aggregation, **Laurence Camoin-Jau**, France

Friday

Venous Thrombosis: Consequences

- **9.00 – 9.15:** Increased mortality risk after venous thrombosis: MEGA follow-up study, **Nienke Wit**, The Netherlands
- **9.15 – 9.30:** Thromboembolic and Bleeding Complications in Patients with Atrial Fibrillation and Liver Cirrhosis – a Population-based Cohort Study, **Emil Zâl Riahi**, Denmark
- **9.30 – 9.45:** Rosuvastatin use decreases FVIII levels by mechanisms not associated with the cholesterol-lowering effect of the drug: results from the START trial, **Willem Lijfering**, The Netherlands
- **9.45 – 10.00:** Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study (STAC), **Rayna Anijs**, The Netherlands

Bleeding in the Clinic

- **9.00 – 9.15:** The VWF variant D1472H affects VWF binding to ristocetin in vitro : the usefulness of measuring VWF activity with the Innovance® VWF:GplbM assay to avoid VWD genotyping, **Fanny Lassalle**, France
- **9.15 – 9.30:** Neither a structured questionnaire at pre-anesthesia visit nor the prescription of routine hemostatic tests have acceptable performances to detect hemostatic abnormalities before surgery, **Nadine Ajzenberg**, France
- **9.30 – 9.45:** The effect of Direct Oral Anticoagulants on bleeding and blood product usage in adults undergoing major cardiac surgery compared to warfarin and control groups, **Christopher Little**, United Kingdom
- **9.45 – 10.00:** Evaluation of Provision of external quality assurance for thromboelastography cartridge based systems: TEG6 and Rotem Sigma, **Dianne Kitchen**, United Kingdom

Clot Structure

- **9.00 – 9.15:** Cells of the macrophage lineage secrete factor (F)XIII-A into the plasma, **Richard Pease**, United Kingdom
- **9.15 – 9.30:** Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis, **Lucas Di Meglio**, France
- **9.30 – 9.45:** Role of the fibrin α C region in mechanical strength, resistance to fibrinolysis and formation of a stable whole blood clot, **Helen Mcpherson**, United Kingdom
- **9.45 – 10.00:** A newly established murine model shows that fibrin γ -chain cross-linking protects against clot embolization, **Cédric Duval**, United Kingdom

Vessel Wall 2

- **9.00 – 9.15:** An endothelial-enriched G protein-coupled receptor regulates tissue factor expression, **Marthe Norreen Thorsen**, Norway
- **9.15 – 9.30:** Evaluation a novel mouse model of abdominal aortic aneurysm to study platelet mechanisms of the proinflammatory thrombus, **Katia Yahiaoui**, France
- **9.30 – 9.45:** Thrombin in complex with dabigatran can still activate PAR-1 on endothelial cells, **Sophie Dolleman**, The Netherlands
- **9.45 – 10.00:** The endothelial-enriched protein KANK3 regulates cell motility and tissue factor expression, **Eike Struck**, Norway

Science, Fast and Furious

- **11.30 – 11.45:** Platelet-derived chemokines CCL5 and CXCL4 are rapidly internalized in endothelial cells, **Annemiek Dickhout**, The Netherlands
- **11.45 – 12.00:** Combined effects of five prothrombotic genotypes and cancer on the risk of venous thromboembolism, **Hanne Skille**, Norway
- **12.00 – 12.15:** ADAMTS13 conformation in the French cohort of child-onset acquired thrombotic thrombocytopenic purpura, **Bérangère Joly**, France
- **12.15 – 12.30:** The importance of the GPIIb/IIIa intracellular tail in VWF- and GPIIb/IIIa-mediated platelet signalling events, **Isabelle Salles-Crawley**, United Kingdom